Table 1 Baseline characteristics (N = 49)
From: Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
Number (%) or Median (IQR) Patients Receiving Amikacin | |
|---|---|
Female | 22 (45%) |
Age | 31 (27, 52) |
BMI | 20.7 (18.8, 22.8) |
Country of Origin | |
Africa | 4 (8%) |
Asia | 40 (82%) |
Eastern Europe | 4 (8%) |
Canada | 1 (2%) |
TB location | |
Pulmonary | 38 (78%) |
Extra-pulmonary | 8 (16%) |
Both | 3 (6%) |
Drug-Susceptibility | |
MDR-TB | 43 (88%) |
Pre-XDR | 5 (10%) |
XDR | 1 (2%) |
Co-morbidity | |
HIV | 1 (2%) |
Diabetes mellitus | 9 (18%) |